Dapagliflozin Cannot Be Recommended as a MASH-Targeted Therapy
According to the most recent 2024 EASL-EASD-EASO guidelines, there is insufficient evidence to recommend dapagliflozin (an SGLT2 inhibitor) as a MASH-targeted therapy; however, it is safe to use in MASLD and should be used for its approved indications—type 2 diabetes, heart failure, and chronic kidney disease. 1
Guideline Position: Strong Consensus Against MASH-Specific Use
The 2024 international guidelines achieved 100% consensus on this recommendation with Level of Evidence 3 1. This means:
- Do not prescribe dapagliflozin specifically to treat MASH histology or fibrosis
- Do prescribe dapagliflozin when patients have comorbid type 2 diabetes, heart failure, or chronic kidney disease for cardiometabolic benefits 1
The guidelines prioritize resmetirom as the only MASH-targeted therapy with demonstrated histological efficacy in large phase III trials for non-cirrhotic MASH with significant fibrosis (stage ≥2) 1.
Why Guidelines Remain Cautious Despite Positive Research
While recent research shows promising results, the guidelines require robust demonstration in large, well-conducted phase III trials before recommending agents as MASH-targeted therapies. Here's the evidence landscape:
Recent Positive Trial Data (2025):
A Chinese multicenter RCT 2 showed dapagliflozin achieved:
- MASH improvement without worsening fibrosis: 53% vs 30% placebo (RR 1.73, P=0.006)
- MASH resolution without worsening fibrosis: 23% vs 8% placebo (RR 2.91, P=0.01)
- Fibrosis improvement without worsening MASH: 45% vs 20% placebo (RR 2.25, P=0.001)
However, this single trial (n=154) does not meet the threshold for guideline-level recommendation requiring multiple large phase III trials.
Important Safety Caveat - Muscle Mass Loss:
A 2025 Japanese RCT 3 revealed a critical safety concern: dapagliflozin was associated with significant decline in skeletal muscle index, indicating risk of sarcopenia. This is clinically significant as muscle loss can worsen overall survival—a key outcome prioritized in clinical decision-making. The vitamin E comparator group did not show this effect.
Clinical implication: If using dapagliflozin for diabetes in MASH patients, monitor muscle mass and implement resistance training protocols.
Practical Clinical Algorithm
For Patients with MASH:
Step 1: Assess for approved dapagliflozin indications
- Type 2 diabetes? → Use dapagliflozin for glycemic control and cardiometabolic benefits 4
- Heart failure (any LVEF)? → Use dapagliflozin for cardiovascular outcomes 4
- Chronic kidney disease (eGFR 25-75)? → Use dapagliflozin for renal protection 4
Step 2: For MASH-specific treatment
- Non-cirrhotic MASH with fibrosis stage ≥2? → Consider resmetirom (if locally approved) 1
- Cirrhotic MASH? → No MASH-targeted pharmacotherapy currently recommended 1
Step 3: Foundational therapy for all
- Weight loss (7-10% body weight target)
- Mediterranean or low-carbohydrate diet
- Exercise ≥150 min/week moderate intensity 1
For Patients with MASH + Type 2 Diabetes Specifically:
First-line approach:
- GLP-1 receptor agonists are preferred for substantial weight loss (which may provide hepatic histological benefit) 1
- SGLT2 inhibitors (including dapagliflozin) are safe alternatives with proven cardiometabolic benefits 1
Monitor if using dapagliflozin:
- Skeletal muscle mass (bioimpedance or DEXA) every 6 months 3
- Volume status (risk of dehydration, especially age ≥65) 4
- Genital mycotic infections 4
Cirrhosis Considerations:
Dapagliflozin can be used in Child-Pugh class A and B cirrhosis per guidelines (92% consensus, weak recommendation) 1, but only for approved indications, not as MASH-targeted therapy.
Common Pitfalls to Avoid
Don't prescribe dapagliflozin solely for MASH treatment without an approved indication—guidelines are clear this lacks sufficient evidence 1
Don't ignore muscle mass monitoring—the sarcopenia risk identified in 3 is particularly concerning in MASH patients who may already have sarcopenic obesity
Don't use in patients with eGFR <25 mL/min/1.73 m² for glycemic control without established cardiovascular disease or risk factors 4
Don't overlook ketoacidosis risk in patients who are fasting, on ketogenic diets, or have reduced oral intake 4
The Bottom Line
Use dapagliflozin when patients with MASLD have type 2 diabetes, heart failure, or chronic kidney disease—it's safe and provides important cardiometabolic benefits that reduce morbidity and mortality. However, do not prescribe it specifically to treat MASH histology or fibrosis, as current evidence does not support this indication according to international guidelines. If MASH-targeted therapy is needed in non-cirrhotic patients with significant fibrosis, resmetirom is the evidence-based choice where available.